BROOKS — Brooks Laboratories Income Statement
0.000.00%
- IN₹4.54bn
- IN₹4.60bn
- IN₹825.57m
Annual income statement for Brooks Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 772 | 912 | 632 | 795 | 826 |
Cost of Revenue | |||||
Gross Profit | 297 | 206 | 62 | 204 | 285 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 838 | 1,126 | 963 | 780 | 792 |
Operating Profit | -65.7 | -214 | -330 | 14.4 | 33.4 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -89.9 | -239 | -384 | -196 | -97.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -194 | -193 | -311 | -196 | -99.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -194 | -113 | -209 | -196 | -99.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -194 | -113 | -209 | -196 | -99.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.75 | -4.56 | -8.47 | -7.65 | -3.72 |